1. Home
  2. Analysis
  3. Ibrutinib
  4. Diffuse-large-b-cell-lymphoma-recurrent

Ibrutinib and Diffuse large b-cell lymphoma recurrent - a phase IV clinical study of FDA data

Summary:

Diffuse large b-cell lymphoma recurrent is reported as a side effect among people who take Ibrutinib (ibrutinib), especially for people who are female, 60+ old, have been taking the drug for 1 - 2 years also take Prednisone, and have Non-hodgkin's lymphoma.

The phase IV clinical study analyzes which people have Diffuse large b-cell lymphoma recurrent when taking Ibrutinib. It is created by eHealthMe based on reports of 13,522 people who have side effects when taking Ibrutinib from the FDA, and is updated regularly.

What is Ibrutinib?

Ibrutinib has active ingredients of ibrutinib. eHealthMe is studying from 13,529 Ibrutinib users. Check the latest studies of Ibrutinib.

What is Diffuse large b-cell lymphoma recurrent?

Diffuse large b-cell lymphoma recurrent (recurrent cancer of b cells, a type of white blood cell) is found to be associated with 74 drugs and 90 conditions by eHealthMe. Check the latest studies of Diffuse large b-cell lymphoma recurrent.

On Jul, 13, 2026

13,522 people reported to have side effects when taking Ibrutinib.
Among them, 60 people (0.44%) have Diffuse large b-cell lymphoma recurrent.

Could Ibrutinib cause Diffuse large b-cell lymphoma recurrent?

Among these 60 people:

How long have people been on Ibrutinib when they have Diffuse large b-cell lymphoma recurrent? *

  • < 1 month: 25.0 %
  • 1 - 6 months: 12.5 %
  • 6 - 12 months: 25.0 %
  • 1 - 2 years: 37.5 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Diffuse large b-cell lymphoma recurrent when taking Ibrutinib? *

  • female: 62 %
  • male: 38 %

What is the age of people who have Diffuse large b-cell lymphoma recurrent when taking Ibrutinib? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 2.22 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 2.22 %
  • 60+: 95.56 %

What are other drugs people take besides Ibrutinib? *

  1. Prednisone: 35 people, 58.33%
  2. Cyclophosphamide: 34 people, 56.67%
  3. Dexamethasone: 30 people, 50.00%
  4. Bendamustine: 27 people, 45.00%
  5. Vincristine Sulfate: 27 people, 45.00%
  6. Cytarabine: 26 people, 43.33%
  7. Methotrexate: 24 people, 40.00%
  8. Temozolomide: 23 people, 38.33%
  9. Bendamustine Hydrochloride: 14 people, 23.33%
  10. Lenalidomide: 13 people, 21.67%

What are other side effects people have besides Diffuse large b-cell lymphoma recurrent? *

  1. Death: 27 people, 45.00%
  2. Confusion: 25 people, 41.67%
  3. Vasogenic Cerebral Oedema (increase in brain water): 25 people, 41.67%
  4. Neurological Symptom (symptoms of nervous system disease): 25 people, 41.67%
  5. Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 22 people, 36.67%
  6. Malignant Neoplasm Progression (cancer tumour came back): 19 people, 31.67%
  7. Disease Progression: 16 people, 26.67%
  8. Neuropathy Peripheral (surface nerve damage): 5 people, 8.33%
  9. Drug Ineffective: 4 people, 6.67%
  10. Pleural Effusion (water on the lungs): 4 people, 6.67%

What are the existing conditions these people have? *

  1. Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 46 people, 76.67%
  2. Diffuse Large B-Cell Lymphoma Stage Iv (cancer of b cells, a type of white blood cell-stage iv): 26 people, 43.33%
  3. Pseudomonas Infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa): 1 person, 1.67%
  4. Malignant Neoplasm Progression (cancer tumour came back): 1 person, 1.67%
  5. Lymphoma (cancer that begins in immune system cells): 1 person, 1.67%
  6. Immunodeficiency Disorders: 1 person, 1.67%
  7. Hypersensitivity: 1 person, 1.67%
  8. Herpes Zoster: 1 person, 1.67%
  9. Fungal Infection: 1 person, 1.67%
  10. Diffuse Large B-Cell Lymphoma Refractory (cancer of b cells, a type of white blood cell-relapsed): 1 person, 1.67%

* Approximation only. Some reports may have incomplete information.

Do you take Ibrutinib and have Diffuse large b-cell lymphoma recurrent?

- Check whether Diffuse large b-cell lymphoma recurrent is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ibrutinib:

Diffuse large b-cell lymphoma recurrent treatments and more:

How severe was Diffuse large b-cell lymphoma recurrent and when was it recovered:

Expand to all the drugs that have ingredients of ibrutinib:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ibrutinib:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Diffuse large b-cell lymphoma recurrent:

Browse all the conditions that are associated with Diffuse large b-cell lymphoma recurrent:

How the study uses the data?

The study uses data from the FDA. It is based on ibrutinib (the active ingredients of Ibrutinib) and Ibrutinib (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.